Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors (Q36498885)

14 August 2017

1 reference

title

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors (English)

1 reference

14 August 2017

Susanne Schiffmann

3

0 references

author name string

Sabine Grösch

series ordinal

1

1 reference

14 August 2017

Thorsten Jürgen Maier

series ordinal

2

1 reference

14 August 2017

Gerd Geisslinger

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Journal of the National Cancer Institute

14 August 2017

1 reference

14 August 2017

98

1 reference

14 August 2017

11

1 reference

14 August 2017

736-747

1 reference

Rofecoxib reduces polyp recurrence in familial polyposis

14 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Sulindac for periampullary polyps in FAP patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

COX-2 inhibition and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Epidemiology of non-steroidal anti-inflammatory drugs and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Expression of proteins related to prostaglandin E2 biosynthesis is increased in human gastric cancer and during gastric carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Role of cyclooxygenases in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Prevention of colorectal cancer through the use of COX-2 selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

NSAIDs and chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase inhibition and mechanisms of colorectal cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cancer and cyclooxygenase-2 (COX-2) inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Coxibs and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Intracellular signal transduction pathways activated by ceramide and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Polyamines and cancer: old molecules, new understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Effect of nonsteroidal anti-inflammatory drugs on beta-catenin protein levels and catenin-related transcription in human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

On the release of cytochrome c from mitochondria during cell death signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib activates a novel mitochondrial apoptosis signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The role of COX-2 inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cellular survival: a play in three Akts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Mitochondrial ceramide and the induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Carbonic anhydrase isozymes IX and XII in gastric tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Aberrant rel/nfkb genes and activity in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Activators and target genes of Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Control of apoptosis by Rel/NF-kappaB transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1,

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib but not rofecoxib inhibits the growth of transformed cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

NF-kappaB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Regulation of life and death by the zinc finger transcription factor Egr-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The role of COX-2 in angiogenesis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Wnt-signalling pathway in ovarian epithelial tumours: increased expression of beta-catenin and GSK3beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Akt participation in the Wnt signaling pathway through Dishevelled

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Identification of c-MYC as a target of the APC pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Induction of apoptosis by R-flurbiprofen in human colon carcinoma cells: involvement of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

Tcf binding sequence and position determines ?-catenin and Lef-1 responsiveness of MMP-7 promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJJ206

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJJ206

1 reference

14 August 2017

1 reference